SI
Imperial
General Calculators
Addiction Medicine
Anesthesiology
APACHE IIEstimate mortality in the critically illBMI and BSA (Mosteller)Calculate BMI and Body Surface Area using Mosteller formulaBMI and BSA (Du Bois)Determine body mass index and body surface area using Du Bois methodACC/AHA CV Risk Calculator (2013)Estimate 10-year risk for atherosclerotic cardiovascular diseaseGlasgow Coma Scale (GCS)Document level of consciousness.Cardiac Output - FickCalculate cardiac output, cardiac index, stroke volume and stroke volume indexPediatric Endotracheal Tube SizeRevised Cardiac Risk Index (Lee Criteria)Rapid pre-op assessment using the Revised Cardiac Risk IndexAsymptomatic ICA (Internal Carotid Artery) Stenosis Surgical Risk StratificationDue Date by LMPPregnancy due date calculatorDue Date by UltrasoundDetermine pregnancy due date using ultrasound resultsGupta Perioperative Cardiac RiskDetermine peri-operative risk for a wide array of surgeries.Postoperative Respiratory Failure Risk CalculatorEstimate risk of postoperative respiratory failureSequential Organ Failure Assessment (SOFA)Document clinical severity in the ICU and predict mortalityVSGNE Ruptured Abdominal Aortic Aneurysm (RAAA) Risk ScoreEstimate mortality after open repair of ruptured AAAPre-test probability of CAD (CAD consortium)Determine pre-test probability of coronary artery disease in patients with chest pain.Vascular Quality Initiative (VQI) Cardiac Risk Index (CRI) | Carotid EndarterectomyEstimate risk of post-op myocardial infarction after carotid endarterectomyVascular Quality Initiative (VQI) Cardiac Risk Index (CRI) | EVAREstimate risk of post-op myocardial infarction after EVARVascular Quality Initiative (VQI) Cardiac Risk Index (CRI) | Infra-inguinal BypassEstimate risk of post-op myocardial infarction after infra-inguinal bypassVascular Quality Initiative (VQI) Cardiac Risk Index (CRI) | Open AAA RepairEstimate risk of post-op myocardial infarction after open AAA repairVQI: Respiratory Adverse Event Risk Post Vascular SurgeryEstimate the risk of pneumonia or respiratory failure after vascular surgeryVascular Quality Initiative (VQI) 30-Day Stroke Risk Index for CEAEstimate risk of stroke within 30 days after carotid endarterectomyVascular Quality Initiative (VQI) 1-Year Mortality Risk Index for CEAEstimate probability of death within 1 year after carotid endarterectomyVascular Quality Initiative (VQI) Cardiac Risk Index (CRI) | Suprainguinal BypassEstimate risk of post-op myocardial infarction after suprainguinal bypassPORT score for PeriOperative Risk of blood Transfusion in cardiac surgery by ACTAPredict risk of blood transfusion after elective cardiac surgery using the ACTA-PORT scoreGeriatric-Sensitive Perioperative Cardiac Risk Index | GSCRIEstimate risk of perioperative myocardial infarction or cardiac arrest in patients over 65STOP-BANG Score for Obstructive Sleep ApneaScreen for obstructive sleep apnea Modified Mallampati Classification Oropharyngeal assessment used for predicting difficulty in laryngoscopy and endotracheal intubation
Cardiac Surgery
Cardiology
Aortic Stenosis/Outflow
Aortic disease
Atrial Fibrillation
Bleeding Risk
Coronary Artery Disease
ECG
Echocardiography
Heart Failure
Hypertension
Invasive Hemodynamics
Miscellaneous
Mitral Regurgitation
Mitral Stenosis
PCI and Cardiac Surgery
Pre-operative Assessment
Risk Scores
Shunts
Syncope
Treadmill Testing
Critical Care
Cardiac ICU
Cardiac Output - FickCalculate cardiac output, cardiac index, stroke volume and stroke volume indexKillip ClassEstimate mortality in myocardial infarctionTIMI Risk Score (NSTEMI)Guide therapeutic decisions in non-ST elevation MI. Shunt Fraction (Invasive)TIMI Risk Score (STEMI)Systemic Vascular ResistanceGRACEThe GRACE ACS risk calculator estimates risk of death following acute coronary syndrome (ACS)Mean Arterial Pressure (MAP) Calculate MAP
REFERENCE BOOK
KDIGO Clinical Practice Guideline for Acute Kidney Injury
AKI Definition Prevention and Treatment of AKI Contrast-induced AKI Dialysis Interventions for Treatment of AKI
Introduction and Methodology
Introduction
IntroductionGlomerular filtration rate and serum creatinineOliguria and anuriaAcute tubular necrosis (ATN)ARFRIFLE criteriaAKI: acute kidney injury/impairmentValidation studies using RIFLELimitations to current definitions for AKIRationale for a guideline on AKISummary
Methodology
IntroductionGroup member selection and meeting processEvidence selection, appraisal, and presentationOutcome selection judgments, values, and preferencesGrading the quality of evidence and the strength of recommendationsSPONSORSHIPDISCLAIMERSUPPLEMENTARY MATERIAL
AKI Definition
Definition and classification of AKI
IntroductionDefinition of AKIStaging AKI: Recommendations and RationaleResearch RecommendationsSupplementary materialRisk assessmentIntroductionRecommendations and RationaleResearch RecommendationsSupplementary material
Evaluation and general management of patients with and at risk for AKI
IntroductionRecommendations and RationaleResearch recommendationsSupplementary material
Clinical applications
IntroductionExamples of application of AKI definitionsEstimating baseline SCrExamples of application of AKI stagesUrine output vs. SCrTimeframe for diagnosis and stagingClinical judgmentPseudo-AKIAtypical AKISupplementary material
Diagnostic approach to alterations in kidney function and structure
Definitions of AKI, CKD and AKDGFR and SCrGFR/SCr algorithmOliguria as a measure of kidney functionKidney damageSmall kidneys as a marker of kidney damageIntegrated approach to AKI, AKD, and CKDSponsorshipDisclaimerSupplementary material
Prevention and Treatment of AKI
Hemodynamic monitoring and support for prevention and management of AKI
IntroductionFluids: Recommendations and RationaleAlbumin vs. SalineHydroxyethylstarch vs. SalineVasopressors: Recommendations and RationaleProtocolized Hemodynamic Management: Recommendations and RationaleProtocolized hemodynamic management strategies in septic shockGoal-directed therapy for hemodynamic support during the perioperative period in high-risk surgical patientsResearch RecommendationsSupplementary material
General supportive management of patients with AKI, including management of complications
Overview
Glycemic control and nutritional support
Glycemic control in critical illness: Recommendations and RationaleNutritional aspects in the prevention and treatment of critically ill patients with AKITotal Energy Intake: Recommendations and RationaleProtein Intake: Recommendations and RationaleNutrition route: Recommendations and RationalePediatrics ConsiderationsResearch RecommendationsSupplementary material
The use of diuretics in AKI
IntroductionRecommendations and RationaleMannitolResearch Recommendations
Vasodilator therapy: dopamine, fenoldopam, and natriuretic peptides
Dopamine for the prevention or treatment of AKI: Recommendations and RationaleFenoldopam for the prevention or treatment of AKI: Recommendations and RationaleResearch RecommendationsNatriuretic peptides for the prevention or treatment of AKI: Recommendations and RationaleResearch RecommendationsSupplementary Material
Growth factor intervention
Recombinant Human (rh) IGF-1: Recommendations and RationaleErythropoietinResearch RecommendationsSupplementary Material
Adenosine receptor antagonists
IntroductionRecommendations and RationaleResearch Recommendations
Prevention of aminoglycoside- and amphotericin-related AKI
Aminoglycoside nephrotoxicityTreatment of Infections: Recommendations and RationalePatients with Normal Kidney Function in Steady State: Recommendations and RationaleWhen Treatment with Multiple Daily Dosing is Used for More than 24 Hours: Recommendations and RationaleWhen Treatment with Single-Daily Dosing is Used for More than 48 Hours: Recommendations and RationaleTopical or Local Applications of Aminoglycosides: Recommendations and RationaleResearch RecommendationsAmphotericin B nephrotoxicity: Recommendations and RationaleTreatment of Systemic Mycoses or Parasitic Infections: Recommendations and RationaleResearch Recommendations
Other methods of prevention of AKI in the critically ill
On-pump vs. off-pump coronary artery bypass surgery: Recommendations and RationaleResearch RecommendationsN-ACETYLCYSTEINE (NAC): Recommendations and RationaleNAC in critically ill patients: Recommendations and RationaleSponsorshipDisclaimerSupplementary Material
Contrast-induced AKI
Contrast-induced AKI: definition, epidemiology, and prognosis
BackgroundRecommendations and RationaleEpidemiology of CI-AKIPrognosis of CI-AKIResearch RecommendationsSupplementary Material
Assessment of the population at risk for CI-AKI
Recommendations and RationaleRisk-factor questionnaireUrinary protein screeningOther risk factors of CI-AKIRisk models of CI-AKIPatients at Increased Risk for CI-AKI: Recommendations and RationaleNephrotoxicity of Gd chelatesNephrogenic systemic fibrosis (NSF)Supplementary Material
Nonpharmacological prevention strategies of CI-AKI
IntroductionDose/Volume of Contrast-Media Administration: Recommendations and RationaleRoute of administration of contrast mediaResearch RecommendationsSelection of a Contrast Agent: Recommendations and RationaleHigh-osmolar vs. iso-osmolar or low-osmolar contrast mediaLow-osmolar vs. iso-osmolar contrast mediai.a. Iodixanol vs. ioxaglatei.v. AdministrationResearch RecommendationsSupplementary Material
Pharmacological prevention strategies of CI-AKI
Fluid Administration: Recommendations and RationaleUse of oral fluids alone in patients at increased risk of CI-AKI: Recommendations and RationaleRole of nac in the prevention of CI-AKI: Recommendations and RationaleTheophylline: Recommendations and RationaleFenoldopam: Recommendations and RationaleStatins in the prevention of CI-AKISupplementary Material
Effects of hemodialysis or hemofiltration
Recommendations and RationaleSponsorshipDisclaimerSupplementary material
Dialysis Interventions for Treatment of AKI
Timing of renal replacement therapy in AKI
IntroductionRecommendations and RationalePediatric considerations
Research Recommendations
Supplementary material
Criteria for stopping renal replacement therapy in AKI
IntroductionWhen to discontinue RRT: Recommendations and RationaleUse of diuretics: Recommendations and RationalePediatric considerationsResearch Recommendations
Anticoagulation
IntroductionHow to decide to use anticoagulation: Recommendations and RationalePatients without an increased bleeding risk or impaired coagulation and not already receiving effective systemic anticoagulation: Recommendations and RationalePatients with increased bleeding risk who are not receiving anticoagulation: Recommendations and RationaleIn patients with heparin-induced thrombocytopenia: Recommendations and RationalePediatric considerationsResearch RecommendationsSupplementary material
Vascular access for renal replacement therapy in AKI
IntroductionUncuffed nontunneled dialysis catheter vs a tunneled catheter: Recommendations and RationaleWhen choosing a vein for insertion of a dialysis catheter in patients with AKI: Recommendations and RationaleUsing ultrasound guidance for dialysis catheter insertion: Recommendations and RationaleObtaining a chest radiograph promptly after placement and before first use of an internal jugular or subclavian dialysis catheter: Recommendations and RationaleTopical antibiotics: Recommendations and RationaleAntibiotic locks: Recommendations and RationalePediatric considerationsResearch RecommendationsSupplementary material
Dialyzer membranes for renal replacement therapy in AKI
IntroductionRecommendations and RationaleResearch Recommendations
Modality of renal replacement therapy for patients with AKI
IntroductionComplementary therapies in AKI patients: Recommendations and RationaleHemodynamically unstable patients: Recommendations and RationaleAKI patients with acute brain injury or other causes of increased intracranial pressure or generalized brain edema: Recommendations and RationaleProtocols for decreasing hemodynamic instability with intermittent RRTPeritoneal dialysisPediatric considerationsResearch RecommendationsSupplementary material
Buffer solutions for renal replacement therapy in patients with AKI
IntroductionBuffer solution: Recommendations and RationaleDialysis fluids and replacement fluids in patients with AKI: Recommendations and RationaleResearch RecommendationsSupplementary material
Dose of renal replacement therapy in AKI
IntroductionDosing: Recommendations and RationaleKt/V and Effluent Volume Rates: Recommendations and RationaleAdditional considerationsResearch RecommendationsSponsorshipDislcaimerSupplementary material
Organization and Acknowledgements
NoticeWork Group MembershipKDIGO Board MembersReference KeysAbbreviations and AcronymsAbstractForewordBiographic and Disclosure InformationAcknowledgmentsReferences
General Medicine
ICU AKI
APACHE IIEstimate mortality in the critically illContrast Nephropathy Post-PCIEstimate risk of AKI after percutaneous coronary interventionDialysis Risk After Cardiac Surgery (Cleveland Clinic Score by Thakar)Estimate risk of dialysis after cardiac surgery.Dialysis Risk After Cardiac Surgery (Mehta)Estimate the risk of dialysis after cardiac surgery (Mehta model)Fractional Excretion of SodiumDifferentiate pre-renal AKI from ATN.Fractional Excretion of UreaIdentify a pre-renal state in patients using diureticsSequential Organ Failure Assessment (SOFA)Document clinical severity in the ICU and predict mortalityPediatric Renal Angina IndexPredict acute kidney injury in critically ill childrenSTARRT-AKI Enrollment CriteriaDetermine if patients meet criteria for the STARRT-AKI study.Kinetic eGFR (KeGFR)Estimate GFR when creatinine is changing acutely (either rising or falling)PIM2Paediatric Index of Mortality, revised versionSerious Renal Dysfunction Post-PCIAssess risk of dialysis or severe increase in creatinine after PCICRRT Dosing CalculatorCalculate desired dose of dialysate in CRRTKDIGO AKI StagingClassification in acute kidney injury (AKI)
REFERENCE BOOK
KDIGO Clinical Practice Guideline for Acute Kidney Injury
AKI Definition Prevention and Treatment of AKI Contrast-induced AKI Dialysis Interventions for Treatment of AKI
Introduction and Methodology
Introduction
IntroductionGlomerular filtration rate and serum creatinineOliguria and anuriaAcute tubular necrosis (ATN)ARFRIFLE criteriaAKI: acute kidney injury/impairmentValidation studies using RIFLELimitations to current definitions for AKIRationale for a guideline on AKISummary
Methodology
IntroductionGroup member selection and meeting processEvidence selection, appraisal, and presentationOutcome selection judgments, values, and preferencesGrading the quality of evidence and the strength of recommendationsSPONSORSHIPDISCLAIMERSUPPLEMENTARY MATERIAL
AKI Definition
Definition and classification of AKI
IntroductionDefinition of AKIStaging AKI: Recommendations and RationaleResearch RecommendationsSupplementary materialRisk assessmentIntroductionRecommendations and RationaleResearch RecommendationsSupplementary material
Evaluation and general management of patients with and at risk for AKI
IntroductionRecommendations and RationaleResearch recommendationsSupplementary material
Clinical applications
IntroductionExamples of application of AKI definitionsEstimating baseline SCrExamples of application of AKI stagesUrine output vs. SCrTimeframe for diagnosis and stagingClinical judgmentPseudo-AKIAtypical AKISupplementary material
Diagnostic approach to alterations in kidney function and structure
Definitions of AKI, CKD and AKDGFR and SCrGFR/SCr algorithmOliguria as a measure of kidney functionKidney damageSmall kidneys as a marker of kidney damageIntegrated approach to AKI, AKD, and CKDSponsorshipDisclaimerSupplementary material
Prevention and Treatment of AKI
Hemodynamic monitoring and support for prevention and management of AKI
IntroductionFluids: Recommendations and RationaleAlbumin vs. SalineHydroxyethylstarch vs. SalineVasopressors: Recommendations and RationaleProtocolized Hemodynamic Management: Recommendations and RationaleProtocolized hemodynamic management strategies in septic shockGoal-directed therapy for hemodynamic support during the perioperative period in high-risk surgical patientsResearch RecommendationsSupplementary material
General supportive management of patients with AKI, including management of complications
Overview
Glycemic control and nutritional support
Glycemic control in critical illness: Recommendations and RationaleNutritional aspects in the prevention and treatment of critically ill patients with AKITotal Energy Intake: Recommendations and RationaleProtein Intake: Recommendations and RationaleNutrition route: Recommendations and RationalePediatrics ConsiderationsResearch RecommendationsSupplementary material
The use of diuretics in AKI
IntroductionRecommendations and RationaleMannitolResearch Recommendations
Vasodilator therapy: dopamine, fenoldopam, and natriuretic peptides
Dopamine for the prevention or treatment of AKI: Recommendations and RationaleFenoldopam for the prevention or treatment of AKI: Recommendations and RationaleResearch RecommendationsNatriuretic peptides for the prevention or treatment of AKI: Recommendations and RationaleResearch RecommendationsSupplementary Material
Growth factor intervention
Recombinant Human (rh) IGF-1: Recommendations and RationaleErythropoietinResearch RecommendationsSupplementary Material
Adenosine receptor antagonists
IntroductionRecommendations and RationaleResearch Recommendations
Prevention of aminoglycoside- and amphotericin-related AKI
Aminoglycoside nephrotoxicityTreatment of Infections: Recommendations and RationalePatients with Normal Kidney Function in Steady State: Recommendations and RationaleWhen Treatment with Multiple Daily Dosing is Used for More than 24 Hours: Recommendations and RationaleWhen Treatment with Single-Daily Dosing is Used for More than 48 Hours: Recommendations and RationaleTopical or Local Applications of Aminoglycosides: Recommendations and RationaleResearch RecommendationsAmphotericin B nephrotoxicity: Recommendations and RationaleTreatment of Systemic Mycoses or Parasitic Infections: Recommendations and RationaleResearch Recommendations
Other methods of prevention of AKI in the critically ill
On-pump vs. off-pump coronary artery bypass surgery: Recommendations and RationaleResearch RecommendationsN-ACETYLCYSTEINE (NAC): Recommendations and RationaleNAC in critically ill patients: Recommendations and RationaleSponsorshipDisclaimerSupplementary Material
Contrast-induced AKI
Contrast-induced AKI: definition, epidemiology, and prognosis
BackgroundRecommendations and RationaleEpidemiology of CI-AKIPrognosis of CI-AKIResearch RecommendationsSupplementary Material
Assessment of the population at risk for CI-AKI
Recommendations and RationaleRisk-factor questionnaireUrinary protein screeningOther risk factors of CI-AKIRisk models of CI-AKIPatients at Increased Risk for CI-AKI: Recommendations and RationaleNephrotoxicity of Gd chelatesNephrogenic systemic fibrosis (NSF)Supplementary Material
Nonpharmacological prevention strategies of CI-AKI
IntroductionDose/Volume of Contrast-Media Administration: Recommendations and RationaleRoute of administration of contrast mediaResearch RecommendationsSelection of a Contrast Agent: Recommendations and RationaleHigh-osmolar vs. iso-osmolar or low-osmolar contrast mediaLow-osmolar vs. iso-osmolar contrast mediai.a. Iodixanol vs. ioxaglatei.v. AdministrationResearch RecommendationsSupplementary Material
Pharmacological prevention strategies of CI-AKI
Fluid Administration: Recommendations and RationaleUse of oral fluids alone in patients at increased risk of CI-AKI: Recommendations and RationaleRole of nac in the prevention of CI-AKI: Recommendations and RationaleTheophylline: Recommendations and RationaleFenoldopam: Recommendations and RationaleStatins in the prevention of CI-AKISupplementary Material
Effects of hemodialysis or hemofiltration
Recommendations and RationaleSponsorshipDisclaimerSupplementary material
Dialysis Interventions for Treatment of AKI
Timing of renal replacement therapy in AKI
IntroductionRecommendations and RationalePediatric considerations
Research Recommendations
Supplementary material
Criteria for stopping renal replacement therapy in AKI
IntroductionWhen to discontinue RRT: Recommendations and RationaleUse of diuretics: Recommendations and RationalePediatric considerationsResearch Recommendations
Anticoagulation
IntroductionHow to decide to use anticoagulation: Recommendations and RationalePatients without an increased bleeding risk or impaired coagulation and not already receiving effective systemic anticoagulation: Recommendations and RationalePatients with increased bleeding risk who are not receiving anticoagulation: Recommendations and RationaleIn patients with heparin-induced thrombocytopenia: Recommendations and RationalePediatric considerationsResearch RecommendationsSupplementary material
Vascular access for renal replacement therapy in AKI
IntroductionUncuffed nontunneled dialysis catheter vs a tunneled catheter: Recommendations and RationaleWhen choosing a vein for insertion of a dialysis catheter in patients with AKI: Recommendations and RationaleUsing ultrasound guidance for dialysis catheter insertion: Recommendations and RationaleObtaining a chest radiograph promptly after placement and before first use of an internal jugular or subclavian dialysis catheter: Recommendations and RationaleTopical antibiotics: Recommendations and RationaleAntibiotic locks: Recommendations and RationalePediatric considerationsResearch RecommendationsSupplementary material
Dialyzer membranes for renal replacement therapy in AKI
IntroductionRecommendations and RationaleResearch Recommendations
Modality of renal replacement therapy for patients with AKI
IntroductionComplementary therapies in AKI patients: Recommendations and RationaleHemodynamically unstable patients: Recommendations and RationaleAKI patients with acute brain injury or other causes of increased intracranial pressure or generalized brain edema: Recommendations and RationaleProtocols for decreasing hemodynamic instability with intermittent RRTPeritoneal dialysisPediatric considerationsResearch RecommendationsSupplementary material
Buffer solutions for renal replacement therapy in patients with AKI
IntroductionBuffer solution: Recommendations and RationaleDialysis fluids and replacement fluids in patients with AKI: Recommendations and RationaleResearch RecommendationsSupplementary material
Dose of renal replacement therapy in AKI
IntroductionDosing: Recommendations and RationaleKt/V and Effluent Volume Rates: Recommendations and RationaleAdditional considerationsResearch RecommendationsSponsorshipDislcaimerSupplementary material
Organization and Acknowledgements
NoticeWork Group MembershipKDIGO Board MembersReference KeysAbbreviations and AcronymsAbstractForewordBiographic and Disclosure InformationAcknowledgmentsReferences
Illness Severity
Medical ICU
Neurologic ICU
Respiratory ICU
Sepsis
Emergency
Airway
Burns
Chest pain & Cardiac
General Medicine
Injuries & Trauma
Pediatrics ER
Psychiatry
Sepsis
Surgery
Thrombosis
Endocrinology
Dubbo Osteoporotic Fracture RiskAssess risk of osteoporotic fracture
REFERENCE BOOK
Obesity in Adults | CTFPHC
Diabetes
Electrolytes
Lipids
Thyroid cancer
Gastroenterology
GI Bleed
Hepatology
Autoimmune Hepatitis DiagnosisClarify the diagnose of autoimmune hepatitisChild Pugh ScoreDetermine severity of cirrhosis.Discriminant Function (Alcoholic Hepatitis)Emory Model (TIPSS)Prognosis after TIPSS using MELD ScorePrognosis in Alcoholic HepatitisEstimates prognosis in alcoholic hepatitis using the MELD scorePELD Score - Age Younger Than 12 yearsPELD (Pediatric End-Stage Liver Disease) is used for liver allocation in the OPTN match systemAlcoholism - Risk of RelapseAlcohol Relapse Risk after Liver TransplantSerum Ascites to Albumin Gradient (SAAG)Determine if ascites due to portal hypertension.FIB-4 for Noninvasive Diagnosis of Hepatic FibrosisNon-invasively identify hepatic fibrosisAPRI (AST to Platelet Ratio Index)Assess likelihood of fibrosis or cirrhosis non-invasively using AST and platelet count.NAFLD Fibrosis ScoreReduce the need for liver biopsy by identifying patients with non-alcoholic fatty liver disease likely or unlikely to have advanced fibrosisMELD Score - Age above 12 yearsScoring system used to rank prioritize candidates for liver transplantation, including MELD-Na used in the OPTN match systemAlcohol Relapse Risk after Liver TransplantMELD Score - Age above 12 yearsScoring system used to rank prioritize candidates for liver transplantation, including MELD-Na used in the OPTN match systemPELD Score - Age Younger Than 12 yearsPELD (Pediatric End-Stage Liver Disease) is used for liver allocation in the OPTN match systemUKELD ScoreThe United Kingdom Model for End-Stage Liver Disease (UKELD) predicts prognosis in chronic liver disease and can be used to prioritize for liver transplantationLille Model for Alcoholic HepatitisEstimate mortality in patients with severe alcoholic hepatitis not responding to corticosteroid therapy BE3A ScoreWhen to treat HCV in decompensated cirrhosis
Inflammatory Bowel Disease
Pancreatitis
Geriatrics
ABCD² ScoreGuide admission in TIA based on ABCD² ScoreACC/AHA CV Risk Calculator (2013)Estimate 10-year risk for atherosclerotic cardiovascular diseaseCHADS2 Score for AFAssess risk of stroke in atrial fibrillationCHA2DS2-VASc Score for AFReplacement for CHADS2 for stroke prediction in atrial fibrillationDubbo Osteoporotic Fracture RiskAssess risk of osteoporotic fractureSyncope - EGSYS ScoreWhich patients with syncope should be admitted?Bleeding Risk in Atrial Fibrillation: HAS-BLED ScoreUnderstand the risk of bleeding from anticoagulation in atrial fibrillationHamilton Depression Rating Scale (HAM-D or HDRS)Determine severity of depressionMGUS PrognosisDetermine risk of malignant progression to myleoma or lymphoproliferative disorder.Pneumonia risk (CURB-65)Estimate prognosis and determine disposition in community-acquired pneumonia.Warfarin Bleeding Risk - ElderlyEstimate 90 day risk of bleeding in patients on warfarin who are >65 yearsWater Deficit in HypernatremiaDetermine water replacement in hypernatremiaPneumonia Severity Index (PORT Score)Determine need for admission in pneumoniaeGFR using CKD-EPICalculate eGFR using the CKD-EPI formulaPatient Health Questionnaire-9 (PHQ-9)Screening tool to assist in identifying major depressive disorderGeriatric Depression ScaleA questionnaire to screen for depression in geriatric populations3-Month Mortality in Incident Elderly ESRD PatientsEstimate the risk of early death (at 3 months) in elderly patients starting dialysis.Predicting 3 Year Survival for Incident Elderly ESRD PatientsDetermine appropriateness for transplant referral in elderly patients starting dialysisGAD-7 Anxiety ScaleScreen for generalized anxiety disorderPolymyalgia Rheumatica (2012 EULAR/ACR Provisional Criteria)Review EULAR/ACR criteria for polymyalgia rheumaticaSan Francisco Syncope RuleIdentify those at low risk of adverse outcome after a syncopal episodeInternational Prostate Symptom Score (IPSS)Assess severity of symptoms in benign prostatic hypertrophyPredicting 3 Year Survival for Incident Elderly ESRD PatientsDetermine appropriateness for transplant referral in elderly patients starting dialysisShort Michigan Alcoholism Screening Test-geriatric version The SMAST-GAssess for problem alcohol drinking in the elderlyGeriatric-Sensitive Perioperative Cardiac Risk Index | GSCRIEstimate risk of perioperative myocardial infarction or cardiac arrest in patients over 65
Depression
Neurocognitive Disorder
Hematology
Benign Hematology
Body Surface Area
Malignant Hematology
CMML Prognostic Scoring Systems (from Spain and Dusseldorf)Assess risk of progression to AML and early mortality in CMMLDiffuse Large B-Cell Lymphoma Prognosis (R-IPI)Determine prognosis in diffuse large B-cell lymphomaFollicular Lymphoma prognosisDetermine prognosis in follicular lymphoma (FLIPI)Acute GVHD GradingDetermine severity in acute graft versus host disease.Hodgkin's Disease | PrognosisEstimate prognosis in Hodgkin's disease.Hematopoietic cell transplantation - specific comorbidity index (HCT-CI)MDS Revised - International Prognostic Scoring System (IPSS-R)Assess mortality and progression to acute myeloid leukemia in myelodysplastic syndromeHodgkin's Marrow InvolvementEstimate likelihood of bone marrow involvement in Hodgkin's lymphoma.MDS Intnl Prognostic Scoring Sys (IPSS)Multiple Myeloma Prognosis (ISS)MASCC Febrile Neutropenia RiskAssess risk in febrile neutropenia and appropriateness for outpatient managementMDS Anemia - EPO/GCSF ResponseIdentify those with MDS likely to respond to stem-cell factors.MDS WHO Classification-based Prognostic Scoring System (WPSS)Estimate survival and risk of transformation to AML in myelodysplastic syndrome.MGUS PrognosisDetermine risk of malignant progression to myleoma or lymphoproliferative disorder.MIPI - Mantle Cell Lymphoma PrognosisEstimate prognosis in mantle cell lymphoma.DIPSS Prognosis in MyelofibrosisEstimate prognosis in myelofibrosis.Smoldering Multiple Myeloma PrognosisDetermine risk of progression to symptomatic multiple myeloma.Diffuse Large B-cell Lymphoma Prognosis (IPI24)Determine prognosis in diffuse large B-cell lymphoma.Diffuse Large B-cell Lymphoma Prognosis (NCCN-IPI)Estimate prognosis in diffuse large B-cell lymphomaDIPSS Plus Score for Prognosis in MyelofibrosisEstimate prognosis in myelofibrosis.Multiple Myeloma Prognosis (R-ISS)Revised international staging system for myelomaCLL-IPIThe International Prognostic Index for patients with chronic lymphocytic leukemiaExpected spleen size Provides upper limit of normal for spleen length and volume by ultrasound relative to body height and gender. MDS Revised - International Prognostic Scoring System (IPSS-R) Non-Age AdjustedAssess mortality and progression to acute myeloid leukemia in myelodysplastic syndrome using the non-age adjusted model
Sponsored
CNS International Prognostic Index in Diffuse Large B-Cell Lymphoma (CNS-IPI)Estimate risk of CNS relapse/progression in diffuse large B-cell lymphomaMALT Lymphoma prognosis (MALT-IPI)Estimate prognosis in MALT lymphomaKhorana risk scoreEstimate risk of chemotherapy-associated thrombosisCLL BALL Score for Relapsed/Refractory CLLSokal Score for CMLEstimate survival in CMLEUTOS Score for Chronic Myelogenous Leukemia (CML)Predict outcomes after CML treatment, adjusted for tyrosine kinase treatments
Infectious Disease
Child Pugh ScoreDetermine severity of cirrhosis.Duke Criteria for EndocarditisDiagnose endocarditisLund-Mackay Sinusitis StageAssess severity of chronic rhinosinusitis and assess response to therapy.MASCC Febrile Neutropenia RiskAssess risk in febrile neutropenia and appropriateness for outpatient managementPrognosis after TIPSS using MELD ScorePediatric Strep ScorePneumonia risk (CURB-65)Estimate prognosis and determine disposition in community-acquired pneumonia.Westley Croup ScoreAssess croup severityPneumonia Severity Index (PORT Score)Determine need for admission in pneumoniaJones Criteria for Diagnosis of Rheumatic FeverDiagnose acute rheumatic feverMELD Score - Age above 12 yearsScoring system used to rank prioritize candidates for liver transplantation, including MELD-Na used in the OPTN match systemMELD Score - Age above 12 yearsScoring system used to rank prioritize candidates for liver transplantation, including MELD-Na used in the OPTN match systemVancomycin Dosing Based on eGFR (creatinine-cystatin C)Select an appropriate initial dose and interval for vancomycin taking into account renal function using cystatin C & creatinineCentor Score (modified) for GAS PharyngitisEstimate likelihood of GAS pharyngitisBoston Criteria for Febrile InfantsIdentify febrile infants aged 28 – 89 days old who are lower risk for serious bacterial infection Rochester Criteria for Febrile InfantsIdentify febrile infants aged ≤ 60 days old who are low-risk for serious bacterial infectionBE3A ScoreWhen to treat HCV in decompensated cirrhosisTB Skin Test InterpretationDetermine likelihood of TB based on tuberculin skin testCanadian Influenza Immunization GuideAdapted from Immunize CanadaAlberta Croup Severity
REFERENCE BOOK
Screening for Hepatitis C | CTFPHCReview Canadian Task Force on Preventive Health Care guideline on Hepatitis C screening
Medical Administration
Medical Imaging
Mental Health
Addictions
Anxiety
Bipolar
Cognition
Depression
Hamilton Depression Rating Scale (HAM-D or HDRS)Determine severity of depressionModified SAD PERSONS ScaleAssess depression with the modified SAD PERSONS ScalePatient Health Questionnaire-9 (PHQ-9)Screening tool to assist in identifying major depressive disorderGeriatric Depression ScaleA questionnaire to screen for depression in geriatric populationsPatient Health Questionnaire-2 (PHQ-2)Ultra-brief screening for depressive disordersAltman Self-Rating Mania Scale (ASRM)5 question scale to screen and stage severity of hypomania/maniaYoung Mania Rating Scale (YMRS)11 question scale to grade the severity of maniaPatient Health Questionnaire-4 (PHQ-4)Ultra-Brief Screening for Anxiety and DepressionCAGE Questionnaire4 question screening for alcohol problemsEdinburgh Postnatal Depression Scale (EPDS)10 question screener for postpartum depressionBipolar Spectrum Diagnostic Scale (BSDS)20 question screener for bipolar spectrum diagnosisWho Five Well Being Index (WHO-5)​5 questions to measure mental well-beingInformant Questionnaire on Cognitive Decline in the Elderly (IQCODE)16 question geriatric cognitive screenerMajor Depression Inventory (MDI)12 question depression severity scaleBrief Psychiatric Rating Scale (BPRS)18 clinical questions to assess severity of consolidated symptoms Generalized Anxiety Disorder 2 (GAD-2)Ultra-brief screening for anxiety disorders
REFERENCE BOOK
Screening for Depression | CTFPHC
Eating Disorder
Obsessive Compulsive Disorder
Pediatrics
Post traumatic stress
Psychosis
Psychosomatic
Nephrology
Acute Kidney Injury
APACHE IIEstimate mortality in the critically illContrast Nephropathy Post-PCIEstimate risk of AKI after percutaneous coronary interventionDialysis Risk After Cardiac Surgery (Cleveland Clinic Score by Thakar)Estimate risk of dialysis after cardiac surgery.Dialysis Risk After Cardiac Surgery (Mehta)Estimate the risk of dialysis after cardiac surgery (Mehta model)Fractional Excretion of SodiumDifferentiate pre-renal AKI from ATN.Fractional Excretion of UreaIdentify a pre-renal state in patients using diureticsSequential Organ Failure Assessment (SOFA)Document clinical severity in the ICU and predict mortalityPediatric Renal Angina IndexPredict acute kidney injury in critically ill childrenSTARRT-AKI Enrollment CriteriaDetermine if patients meet criteria for the STARRT-AKI study.Kinetic eGFR (KeGFR)Estimate GFR when creatinine is changing acutely (either rising or falling)PIM2Paediatric Index of Mortality, revised versionSerious Renal Dysfunction Post-PCIAssess risk of dialysis or severe increase in creatinine after PCICRRT Dosing CalculatorCalculate desired dose of dialysate in CRRTNCDR AKI and Dialysis Risk after PCIEstimate risk of AKI and dialysis after PCIAdvanced CKD after AKI Risk IndexEstimate risk of advanced chronic kidney disease after acute kidney injuryMayo AKI Risk after Primary Total Hip ArthroplastyEstimate perioperative risk of acute kidney injuryKDIGO AKI StagingClassification in acute kidney injury (AKI)
REFERENCE BOOK
KDIGO Clinical Practice Guideline for Acute Kidney Injury
AKI Definition Prevention and Treatment of AKI Contrast-induced AKI Dialysis Interventions for Treatment of AKI
Introduction and Methodology
Introduction
IntroductionGlomerular filtration rate and serum creatinineOliguria and anuriaAcute tubular necrosis (ATN)ARFRIFLE criteriaAKI: acute kidney injury/impairmentValidation studies using RIFLELimitations to current definitions for AKIRationale for a guideline on AKISummary
Methodology
IntroductionGroup member selection and meeting processEvidence selection, appraisal, and presentationOutcome selection judgments, values, and preferencesGrading the quality of evidence and the strength of recommendationsSPONSORSHIPDISCLAIMERSUPPLEMENTARY MATERIAL
AKI Definition
Definition and classification of AKI
IntroductionDefinition of AKIStaging AKI: Recommendations and RationaleResearch RecommendationsSupplementary materialRisk assessmentIntroductionRecommendations and RationaleResearch RecommendationsSupplementary material
Evaluation and general management of patients with and at risk for AKI
IntroductionRecommendations and RationaleResearch recommendationsSupplementary material
Clinical applications
IntroductionExamples of application of AKI definitionsEstimating baseline SCrExamples of application of AKI stagesUrine output vs. SCrTimeframe for diagnosis and stagingClinical judgmentPseudo-AKIAtypical AKISupplementary material
Diagnostic approach to alterations in kidney function and structure
Definitions of AKI, CKD and AKDGFR and SCrGFR/SCr algorithmOliguria as a measure of kidney functionKidney damageSmall kidneys as a marker of kidney damageIntegrated approach to AKI, AKD, and CKDSponsorshipDisclaimerSupplementary material
Prevention and Treatment of AKI
Hemodynamic monitoring and support for prevention and management of AKI
IntroductionFluids: Recommendations and RationaleAlbumin vs. SalineHydroxyethylstarch vs. SalineVasopressors: Recommendations and RationaleProtocolized Hemodynamic Management: Recommendations and RationaleProtocolized hemodynamic management strategies in septic shockGoal-directed therapy for hemodynamic support during the perioperative period in high-risk surgical patientsResearch RecommendationsSupplementary material
General supportive management of patients with AKI, including management of complications
Overview
Glycemic control and nutritional support
Glycemic control in critical illness: Recommendations and RationaleNutritional aspects in the prevention and treatment of critically ill patients with AKITotal Energy Intake: Recommendations and RationaleProtein Intake: Recommendations and RationaleNutrition route: Recommendations and RationalePediatrics ConsiderationsResearch RecommendationsSupplementary material
The use of diuretics in AKI
IntroductionRecommendations and RationaleMannitolResearch Recommendations
Vasodilator therapy: dopamine, fenoldopam, and natriuretic peptides
Dopamine for the prevention or treatment of AKI: Recommendations and RationaleFenoldopam for the prevention or treatment of AKI: Recommendations and RationaleResearch RecommendationsNatriuretic peptides for the prevention or treatment of AKI: Recommendations and RationaleResearch RecommendationsSupplementary Material
Growth factor intervention
Recombinant Human (rh) IGF-1: Recommendations and RationaleErythropoietinResearch RecommendationsSupplementary Material
Adenosine receptor antagonists
IntroductionRecommendations and RationaleResearch Recommendations
Prevention of aminoglycoside- and amphotericin-related AKI
Aminoglycoside nephrotoxicityTreatment of Infections: Recommendations and RationalePatients with Normal Kidney Function in Steady State: Recommendations and RationaleWhen Treatment with Multiple Daily Dosing is Used for More than 24 Hours: Recommendations and RationaleWhen Treatment with Single-Daily Dosing is Used for More than 48 Hours: Recommendations and RationaleTopical or Local Applications of Aminoglycosides: Recommendations and RationaleResearch RecommendationsAmphotericin B nephrotoxicity: Recommendations and RationaleTreatment of Systemic Mycoses or Parasitic Infections: Recommendations and RationaleResearch Recommendations
Other methods of prevention of AKI in the critically ill
On-pump vs. off-pump coronary artery bypass surgery: Recommendations and RationaleResearch RecommendationsN-ACETYLCYSTEINE (NAC): Recommendations and RationaleNAC in critically ill patients: Recommendations and RationaleSponsorshipDisclaimerSupplementary Material
Contrast-induced AKI
Contrast-induced AKI: definition, epidemiology, and prognosis
BackgroundRecommendations and RationaleEpidemiology of CI-AKIPrognosis of CI-AKIResearch RecommendationsSupplementary Material
Assessment of the population at risk for CI-AKI
Recommendations and RationaleRisk-factor questionnaireUrinary protein screeningOther risk factors of CI-AKIRisk models of CI-AKIPatients at Increased Risk for CI-AKI: Recommendations and RationaleNephrotoxicity of Gd chelatesNephrogenic systemic fibrosis (NSF)Supplementary Material
Nonpharmacological prevention strategies of CI-AKI
IntroductionDose/Volume of Contrast-Media Administration: Recommendations and RationaleRoute of administration of contrast mediaResearch RecommendationsSelection of a Contrast Agent: Recommendations and RationaleHigh-osmolar vs. iso-osmolar or low-osmolar contrast mediaLow-osmolar vs. iso-osmolar contrast mediai.a. Iodixanol vs. ioxaglatei.v. AdministrationResearch RecommendationsSupplementary Material
Pharmacological prevention strategies of CI-AKI
Fluid Administration: Recommendations and RationaleUse of oral fluids alone in patients at increased risk of CI-AKI: Recommendations and RationaleRole of nac in the prevention of CI-AKI: Recommendations and RationaleTheophylline: Recommendations and RationaleFenoldopam: Recommendations and RationaleStatins in the prevention of CI-AKISupplementary Material
Effects of hemodialysis or hemofiltration
Recommendations and RationaleSponsorshipDisclaimerSupplementary material
Dialysis Interventions for Treatment of AKI
Timing of renal replacement therapy in AKI
IntroductionRecommendations and RationalePediatric considerations
Research Recommendations
Supplementary material
Criteria for stopping renal replacement therapy in AKI
IntroductionWhen to discontinue RRT: Recommendations and RationaleUse of diuretics: Recommendations and RationalePediatric considerationsResearch Recommendations
Anticoagulation
IntroductionHow to decide to use anticoagulation: Recommendations and RationalePatients without an increased bleeding risk or impaired coagulation and not already receiving effective systemic anticoagulation: Recommendations and RationalePatients with increased bleeding risk who are not receiving anticoagulation: Recommendations and RationaleIn patients with heparin-induced thrombocytopenia: Recommendations and RationalePediatric considerationsResearch RecommendationsSupplementary material
Vascular access for renal replacement therapy in AKI
IntroductionUncuffed nontunneled dialysis catheter vs a tunneled catheter: Recommendations and RationaleWhen choosing a vein for insertion of a dialysis catheter in patients with AKI: Recommendations and RationaleUsing ultrasound guidance for dialysis catheter insertion: Recommendations and RationaleObtaining a chest radiograph promptly after placement and before first use of an internal jugular or subclavian dialysis catheter: Recommendations and RationaleTopical antibiotics: Recommendations and RationaleAntibiotic locks: Recommendations and RationalePediatric considerationsResearch RecommendationsSupplementary material
Dialyzer membranes for renal replacement therapy in AKI
IntroductionRecommendations and RationaleResearch Recommendations
Modality of renal replacement therapy for patients with AKI
IntroductionComplementary therapies in AKI patients: Recommendations and RationaleHemodynamically unstable patients: Recommendations and RationaleAKI patients with acute brain injury or other causes of increased intracranial pressure or generalized brain edema: Recommendations and RationaleProtocols for decreasing hemodynamic instability with intermittent RRTPeritoneal dialysisPediatric considerationsResearch RecommendationsSupplementary material
Buffer solutions for renal replacement therapy in patients with AKI
IntroductionBuffer solution: Recommendations and RationaleDialysis fluids and replacement fluids in patients with AKI: Recommendations and RationaleResearch RecommendationsSupplementary material
Dose of renal replacement therapy in AKI
IntroductionDosing: Recommendations and RationaleKt/V and Effluent Volume Rates: Recommendations and RationaleAdditional considerationsResearch RecommendationsSponsorshipDislcaimerSupplementary material
Organization and Acknowledgements
NoticeWork Group MembershipKDIGO Board MembersReference KeysAbbreviations and AcronymsAbstractForewordBiographic and Disclosure InformationAcknowledgmentsReferences
Chronic Kidney Disease
Fluids & Electrolytes
Glomerulonephritis
Hemodialysis
Hypertension
Nephrolithiasis
PD
PD Candidacy (MATCH-D)Assess candidacy for peritoneal dialysis3-Month Mortality in Incident Elderly ESRD PatientsEstimate the risk of early death (at 3 months) in elderly patients starting dialysis.Predicting 3 Year Survival for Incident Elderly ESRD PatientsDetermine appropriateness for transplant referral in elderly patients starting dialysisPredicting 3 Year Survival for Incident Elderly ESRD PatientsDetermine appropriateness for transplant referral in elderly patients starting dialysis
REFERENCE BOOK
Access Care and Complications Management
Sponsored
OverviewDisclaimer & Use of the Guide
Catheter Insertion and Care
Preoperative Management
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes Evaluation
Perioperative and Intraoperative Management
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes Evaluation
Postoperative Management
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes Evaluation
Chronic Care of Peritoneal Dialysis Catheter
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationReferences
Noninfectious Complications
Pericatheter and Subcutaneous Leaks
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationManagementReferences
Peritoneal Catheter Obstruction
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationReferences
Hernia
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationReferences
Abdominal Discomfort During Infusion and Drain
Key AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationReferences
Pneumoperitoneum (Shoulder Pain)
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationReferences
Hemoperitoneum
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationReferences
Hydrothorax
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationReferences
Catheter Adapter Disconnect or Fracture of Peritoneal Catheter
Key AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationReferences
Infectious Complications: Peritonitis Management
Initial Empiric Management of Peritonitis
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationInitial Empiric Management of PeritonitisStaphyloccocus aureus PeritonitisEnterococcus PeritonitisStreptococcus PeritonitisPseudomonas aeruginosa PeritonitisGram-negative Bacilli Organism PeritonitisPolymicrobial PeritonitisCulture-negative PeritonitisFungal PeritonitisMycobacterium PeritonitisPeritonitis TerminologyCoagulase-negative StaphylococciRelapsing and Repeat PeritonitisReferencesDisclaimer
Infectious Complications: Management of the Exit-site/Tunnel Infection
Introduction
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationDiagnosis and Management of Exit-site/Tunnel InfectionReferencesDisclaimer
Antibiotic Dosing Guidelines
Oral Antibiotics Used in Exit-site and Tunnel InfectionsExit-site Antibiotic ProphylaxisIntraperitoneal Antibiotic Dosing Recommendations for CAPD PatientsIntermittent Dosing of Antibiotics in Automated Peritoneal Dialysis (APD)References
Surgical Salvage Procedures for Infectious Complications
Simultaneous Catheter Replacement for Relapsing Peritonitis
Key AssessmentsKey ActivitiesPatient EducationOutcomes Evaluation
Exit-Site and Tunnel Infections
Key AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationReferences
Appendix
Preoperative and Postoperative PD Catheter Insertion Instructions for PatientsPeritoneal ImagingPrinciples of Accurate Peritoneal Dialysis Effluent Sampling and CulturingPeritoneal Effluent Culture Laboratory ProcessingPeritonitis Rate CalculationsDifferential Diagnosis of Non-infectious Cloudy EffluentProviding for a Safe Environment for Peritoneal DialysisNormal Bacterial Flora of the Human Body
Preoperative Mapping
IntroductionPreoperative Mapping Using a Catheter SampleStencil-Based Preoperative MappingPreoperative Mapping for Upper Abdominal and Presternal CathetersProcedure Day MappingReferencesCalculating Peritonitis Rates: An ExampleAuthor AffiliationsAccess Care and Complications Management   link ⇲
REFERENCE BOOK
CSN PD Adequacy Guidelines and Recommendations 2011
Maintenance of RRF
Measurement of RRFUse of Antihypertensive Agents and Diuretis to Preserve RRF
Small-Solute Clearance
Prescription and Targets
Volume Management
Maintenance of Euvolemia and Diagnosis of HypervolemiaTreatment of HypervolemiaAssessment and Management of BP
Management of CV Disease in PD Patients
Dyslipidemia
Nutrition in PD
NutritionNutritional SupplementsCorrection of Impared Anabolism, Acidosis, and Gastroparesis
Management of Hyperglycemia
Glycemic ControlGlucose-Sparing Strategies
Introduction
OverviewMethods and Process for Guideline DevelopmentFigure 1Figure 2Figure 3
Maintenance of RRF
Measurement of RRF
Overview
Use of Antihypertensive Agents and Diuretics to Preserve RRF
OverviewBackground
Research
Overview
Small-Solute Clearance
Prescriptions and Targets
OverviewBackground
Volume Management
Maintenance of Euvolemia and Diagnosis of Hypervolemia
OverviewBackground
Treatment of Hypervolemia
OverviewBackground
Assessment and Management of BP
OverviewBackground
Management of CV Disease in PD Patients
Dyslipidemia
OverviewBackground
Coronary Artery Disease/Chronic Heart Failure
Overview
Research
Overview
Nutrition in PD
Nutrition
OverviewBackground
Nutritional Supplements
OverviewBackground
Correction of Impaired Anabolism, Acidosis, and Gastroparesis
OverviewBackground
Research
Overview
Management of Hyperglycemia
Glycemic Control
OverviewBackground
Glucose-Sparing Strategies
OverviewBackgroundDisclosuresReferences
REFERENCE BOOK
PD Prescription Quick Reference Guide
Sponsored
REFERENCE BOOK
PD Prescription Management Guide
Sponsored
Pathology
Polycystic Kidney Disease
Thrombotic Microangiopathy
Transplant
eGFR
Neurology / Neurosurgery
Arteriovenous Malformation
Coma/Level of Consciousness
Dementia/Neurodegenerative
Demyelinating Disease
Dermatome Map
Functional Outcome
Head & Neck Trauma
Headache
Intracerebral Hemorrhage
Ischemic Stroke
Neurophysiology
Seizure
Subarachnoid Hemorrhage
Thrombotic Microangiopathy
Obstetrics
Oncology
Body Surface Area
Head & Neck Cancer Staging
Malignant Hematology
CMML Prognostic Scoring Systems (from Spain and Dusseldorf)Assess risk of progression to AML and early mortality in CMMLDiffuse Large B-Cell Lymphoma Prognosis (R-IPI)Determine prognosis in diffuse large B-cell lymphomaFollicular Lymphoma prognosisDetermine prognosis in follicular lymphoma (FLIPI)Acute GVHD GradingDetermine severity in acute graft versus host disease.Hodgkin's Disease | PrognosisEstimate prognosis in Hodgkin's disease.Hematopoietic cell transplantation - specific comorbidity index (HCT-CI)MDS Revised - International Prognostic Scoring System (IPSS-R)Assess mortality and progression to acute myeloid leukemia in myelodysplastic syndromeHodgkin's Marrow InvolvementEstimate likelihood of bone marrow involvement in Hodgkin's lymphoma.MDS Intnl Prognostic Scoring Sys (IPSS)Multiple Myeloma Prognosis (ISS)MASCC Febrile Neutropenia RiskAssess risk in febrile neutropenia and appropriateness for outpatient managementMDS Anemia - EPO/GCSF ResponseIdentify those with MDS likely to respond to stem-cell factors.MDS WHO Classification-based Prognostic Scoring System (WPSS)Estimate survival and risk of transformation to AML in myelodysplastic syndrome.MGUS PrognosisDetermine risk of malignant progression to myleoma or lymphoproliferative disorder.MIPI - Mantle Cell Lymphoma PrognosisEstimate prognosis in mantle cell lymphoma.DIPSS Prognosis in MyelofibrosisEstimate prognosis in myelofibrosis.Smoldering Multiple Myeloma PrognosisDetermine risk of progression to symptomatic multiple myeloma.Diffuse Large B-cell Lymphoma Prognosis (IPI24)Determine prognosis in diffuse large B-cell lymphoma.Diffuse Large B-cell Lymphoma Prognosis (NCCN-IPI)Estimate prognosis in diffuse large B-cell lymphomaDIPSS Plus Score for Prognosis in MyelofibrosisEstimate prognosis in myelofibrosis.Multiple Myeloma Prognosis (R-ISS)Revised international staging system for myelomaCLL-IPIThe International Prognostic Index for patients with chronic lymphocytic leukemiaMDS Revised - International Prognostic Scoring System (IPSS-R) Non-Age AdjustedAssess mortality and progression to acute myeloid leukemia in myelodysplastic syndrome using the non-age adjusted model
Sponsored
CNS International Prognostic Index in Diffuse Large B-Cell Lymphoma (CNS-IPI)Estimate risk of CNS relapse/progression in diffuse large B-cell lymphomaMALT Lymphoma prognosis (MALT-IPI)Estimate prognosis in MALT lymphomaKhorana risk scoreEstimate risk of chemotherapy-associated thrombosisCLL BALL Score for Relapsed/Refractory CLLSokal Score for CMLEstimate survival in CMLEUTOS Score for Chronic Myelogenous Leukemia (CML)Predict outcomes after CML treatment, adjusted for tyrosine kinase treatments
Solid Tumor
NSCLC StageCarboplatin AUC Dosing (Calvert)Prognosis in Renal Cell Carcinoma (UISS)Estimate survival in renal cell carcinomaBrain Metastases Prognostic IndexEstimate prognosis in patients with brain metastases using the graded prognostic assessmentSerious Illness Conversation GuideSteps to elicit important information from your patients about their goals and valuesKhorana risk scoreEstimate risk of chemotherapy-associated thrombosis
REFERENCE BOOK
Screening for Breast Cancer | CTFPHC
REFERENCE BOOK
Screening for Colorectal Cancer | CTFPHC
REFERENCE BOOK
Screening for Lung Cancer | CTFPHC
REFERENCE BOOK
Screening for Prostate Cancer | CTFPHC
REFERENCE BOOK
Screening for Cervical Cancer | CTFPHC
Orthopedics
Otolaryngology (ENT)
Pediatrics
APGARNewborn assessmentSNAP-IV 26 - Teacher & Parent Rating ScaleAssess children for attention deficit hyperactivity disorder (ADHD)Pediatric Endotracheal Tube SizePediatric Glasgow Coma ScalePediatric Strep ScorePELD Score - Age Younger Than 12 yearsPELD (Pediatric End-Stage Liver Disease) is used for liver allocation in the OPTN match systemWestley Croup ScoreAssess croup severityPIM2Paediatric Index of Mortality, revised versionPCDAIPediatric Crohn's Disease Activity IndexPELD Score - Age Younger Than 12 yearsPELD (Pediatric End-Stage Liver Disease) is used for liver allocation in the OPTN match systemCentor Score (modified) for GAS PharyngitisEstimate likelihood of GAS pharyngitisPhiladelphia Criteria in Febrile Infants Identify febrile infants aged 29 – 56 days old who are lower risk for serious bacterial infection Boston Criteria for Febrile InfantsIdentify febrile infants aged 28 – 89 days old who are lower risk for serious bacterial infection Rochester Criteria for Febrile InfantsIdentify febrile infants aged ≤ 60 days old who are low-risk for serious bacterial infectionPECARN Rule for Pediatric Head Injury < 2 years oldAssess the need for neuroimaging in pediatric head trauma PECARN Rule for Pediatric Head Injury ≥ 2 years oldAssess the need for neuroimaging in pediatric head trauma PRAM Score for Pediatric Asthma Exacerbation SeverityAssess asthma severity in pediatric patientsAlberta Croup Severity
REFERENCE BOOK
Tobacco Smoking in Children and Adolescents | CTFPHC
REFERENCE BOOK
Screening for Developmental Delay | CTFPHCReview Canadian Task Force on Preventive Health Care guideline on screening for developmental delay
REFERENCE BOOK
Obesity in Children | CTFPHC
REFERENCE BOOK
Diagnosis and Management of Congenital Diaphragmatic Hernia (CDH): A Clinical Practice Guideline
Physical Medicine and Rehabilitation
Physiotherapy
Preventive Medicine
ACC/AHA CV Risk Calculator (2013)Estimate 10-year risk for atherosclerotic cardiovascular disease
REFERENCE BOOK
Screening for Breast Cancer | CTFPHC
REFERENCE BOOK
Screening for Cervical Cancer | CTFPHC
REFERENCE BOOK
Screening for Hypertension | CTFPHC
REFERENCE BOOK
Screening for Type 2 Diabetes | CTFPHC
REFERENCE BOOK
Tobacco Smoking in Children and Adolescents | CTFPHC
REFERENCE BOOK
Screening for Colorectal Cancer | CTFPHC
REFERENCE BOOK
Screening for Cognitive Impairment | CTFPHC
REFERENCE BOOK
Screening for Depression | CTFPHC
REFERENCE BOOK
Screening for Developmental Delay | CTFPHCReview Canadian Task Force on Preventive Health Care guideline on screening for developmental delay
REFERENCE BOOK
Screening for Lung Cancer | CTFPHC
REFERENCE BOOK
Obesity in Adults | CTFPHC
REFERENCE BOOK
Obesity in Children | CTFPHC
REFERENCE BOOK
Pelvic Exam | CTFPHC
REFERENCE BOOK
Screening for Prostate Cancer | CTFPHC
REFERENCE BOOK
Screening for Hepatitis C | CTFPHCReview Canadian Task Force on Preventive Health Care guideline on Hepatitis C screening
REFERENCE BOOK
Screening for Abdominal Aortic Aneurysm | CTFPHC
REFERENCE BOOK
Impaired Vision | CTFPHC
REFERENCE BOOK
Screening for Asymptomatic Bacteriuria in Pregnancy | CTFPHC
Respirology
Asthma & COPD
DVT/PE
General Respirology
Lung Cancer
Pneumonia
Sleep
Rheumatology
Ankylosing Spondylitis
Diagnostic criteria
Lupus
Rheumatoid Arthritis
Vasculitis
Surgery
Inflammatory Bowel Disease
Preoperative Assessment
Surgical diagnosis & management
Trauma
WHO Surgical Safety Checklist
Transplant
Renal Graft Failure at 5-Years, Predicted 1 Year Post TransplantEstimate the risk of kidney transplant graft failure at 5 yearsRenal Graft Failure at 5-Years, Predicted 7 Days Post TransplantEstimate the risk of kidney transplant graft failure at 5 yearsRenal Graft Failure at 5-Years, Predicted at Time of TransplantEstimate the risk of kidney transplant graft failure at 5 yearsPELD Score - Age Younger Than 12 yearsPELD (Pediatric End-Stage Liver Disease) is used for liver allocation in the OPTN match systemAlcohol Relapse Risk after Liver TransplantGupta Perioperative Cardiac RiskDetermine peri-operative risk for a wide array of surgeries.Postoperative Respiratory Failure Risk CalculatorEstimate risk of postoperative respiratory failurePredicting 3 Year Survival for Incident Elderly ESRD PatientsDetermine appropriateness for transplant referral in elderly patients starting dialysisMELD Score - Age above 12 yearsScoring system used to rank prioritize candidates for liver transplantation, including MELD-Na used in the OPTN match systemAlcohol Relapse Risk after Liver TransplantMELD Score - Age above 12 yearsScoring system used to rank prioritize candidates for liver transplantation, including MELD-Na used in the OPTN match systemPELD Score - Age Younger Than 12 yearsPELD (Pediatric End-Stage Liver Disease) is used for liver allocation in the OPTN match systemPredicting 3 Year Survival for Incident Elderly ESRD PatientsDetermine appropriateness for transplant referral in elderly patients starting dialysisRenal Graft Failure at 5-Years, Predicted 1 Year Post TransplantEstimate the risk of kidney transplant graft failure at 5 yearsRenal Graft Failure at 5-Years, Predicted 7 Days Post TransplantEstimate the risk of kidney transplant graft failure at 5 yearsRenal Graft Failure at 5-Years, Predicted at Time of TransplantEstimate the risk of kidney transplant graft failure at 5 yearsUKELD ScoreThe United Kingdom Model for End-Stage Liver Disease (UKELD) predicts prognosis in chronic liver disease and can be used to prioritize for liver transplantation
Urology
Nephrolithiasis
Preoperative Assessment
Thrombosis
Urologic disease
WHO Surgical Safety Checklist
Vascular Surgery
Surgical diagnosis & management
Vascular Quality Initiative Tools
WHO Surgical Safety Checklist
REFERENCE BOOK

KDIGO Clinical Practice Guideline for Acute Kidney Injury
Biographic and Disclosure Information

Biographic and Disclosure Information

John A Kellum, MD, FCCM, FACP (Work Group Co-Chair), is Professor of Critical Care Medicine, Medicine, Bioengineering and Clinical and Translational Science, and Vice Chair for Research within the Department of Critical Care Medicine at the University of Pittsburgh. In addition, he is the Director of the Program on Bioengineering and Organ Support for the CRISMA (Clinical Research Investigation and Systems Modeling of Acute Illness) Center at the University of Pittsburgh.

Dr Kellum is actively involved in education, research, and administration. His research interests span various aspects of critical-care medicine, but center in critical-care nephrology, sepsis, multiorgan failure, and clinical epidemiology, including consensus development and research methodology. He has authored more than 300 publications and served as editor and contributor to recent texts including Continuous Renal Replacement Therapy, Critical Care Nephrology, and Management of Acute Kidney Problems. Dr Kellum has won several awards for teaching and has given more than 400 seminars and invited lectures worldwide related to his research.

Advisor/Consultant: Abbott; Alere; Astute Medical; Baxter; CytoSorbents; EBI; Eli Lilly; Fresenius; Gambro; Siemens; Spectral Diagnostics

Speaker: Baxter; Fresenius; Gambro

Grant/Research Support: Astute Medical; Baxter; CytoSorbents; Gambro

Norbert Lameire, MD, PhD (Work Group Co-Chair), is Professor of Internal Medicine and former Chief of Renal Division at the University of Ghent where he also received his medical degree and PhD. Dr Lameire’s interests include basic research topics such as renal circulation in experimental ARF and peritoneal circulation, as well as clinical topics spanning clinical ARF, PD, and organizational and economic aspects of chronic RRT and transplantation. He currently oversees the worldwide continuing medical education programs of COMGAN of the International Society of Nephrology, and serves as current Editor-in-Chief for Acta Clinica Belgica and is emeritus Editor-in-Chief for Nephrology Dialysis Transplantation. For his activities in the Renal Sister Program of the International Society of Nephrology and his leadership of the Renal Disaster Relief Task Force, he was awarded Doctor Honoris Causa at the Kaunas Medical Academy in Lithuania and an honorary membership of the International Society of Nephrology (ISN). Dr Lameire also received the Garabed Eknoyan Award from the NKF (USA) in 2007 for his continuing work to improve dialysis therapy and PD, and his contributions to improving and implementing KDOQI Guidelines. He also served as the KDIGO Co-Chair from 2004 to 2007.

Dr Lameire reported no relevant financial relationships.

Peter Aspelin, MD, PhD, received his basic training in radiology at Malmo¨ University Hospital (Lund University) and was Associate Professor there for 13 years. In 1989 he became Professor and Chairman of the Department of Radiology at Karolinska Institutet, Huddinge University Hospital. Professor Aspelin was Vice Dean of the Medical School at Karolinska Institutet from 1993 to 1995 and served as Vice President at the institution from 1995 to 2001. He was also Head of Research & Development at Huddinge University Hospital in 2002 and Vice Chairman of Research & Development at the Karolinska University Hospital. Other notable accomplishments also include his roles as President for the Scientific Board of the Swedish Council of Technology Assessment in Health Care (1999–2005); Chairman of the Swedish Society of Medical Radiology (2003–2005); and past Vice Chairman and current Chairman of the Swedish Medical Association.

Professor Aspelin has conducted research on contrast media since 1972 when he studied under the tutelage of Professor Torsten Almen. He has written more than 170 scientific publications to date and his primary research centers on the development of nonionic contrast media and the examination of their effects on medical imaging and patient safety.

Speaker: GE Healthcare

Expert witness: GE Healthcare

Rashad S Barsoum, MD, FRCP, FRCPE, is Emeritus Professor of Medicine at Cairo University and current Chairman of Cairo Kidney Center and Medical Sector Committee for Supreme Council for Egyptian Universities. He received his medical degree from Cairo University, where he also completed his fellowship in nephrology in 1967. Dr Barsoum has been a primary investigator in clinical trials involving the study of immunosuppression agents in kidney transplantation and treatment of HCV infection in dialysis patients. He has also authored more than 200 journal articles and book chapters and currently serves as Associate Editor for Nephron Clinical Practice and editorial board member for American Journal of Kidney Diseases. Dr Barsoum is also active in numerous medical societies, having served as Past President for the Arab Society of Nephrology and Renal Transplantation and Egyptian Society of Nephrology. Among his noted achievements include the International Award from the NKF (USA), the Roscoe Robinson Award from the International Society of Nephrology, and the Distinguished Researcher Award from Cairo University.

Advisor/Consultant: Wyeth

Speaker: Amgen; B. Braun; Fresenius; Janssen Cilag; Novartis; Roche; Wyeth

Emmanuel A Burdmann, MD, PhD, is Head of Intensive Care Unit and Associate Professor, Division of Nephrology at University of Sao Paulo Medical School. He received his medical degree from the University of Sao Paulo, where he also completed his fellowship. He was the Past President of the Latin American Society of Nephrology and Hypertension and current President of Brazilian Society of Nephrology. Dr Burdmann has authored over 150 journal articles and book chapters and is currently on the editorial boards of Clinical Journal of the American Society of Nephrology, Clinical Nephrology, Kidney International, Nephrology Dialysis Transplantation, and Nephron Clinical Practice. He is also a member of numerous professional societies and has served on the Council of the International Society of Nephrology and KDIGO Board. In addition to his research interest in AKI, Dr Burdmann is also a coinvestigator in the TREAT study.

Dr Burdmann reported no relevant financial relationships.

Stuart L Goldstein, MD, is Professor of Pediatrics and Director, Center for Acute Care Nephrology at Cincinnati Children’s Hospital Medical Center. He received his medical degree from Columbia University and completed both clinical and research fellowships in pediatric nephrology at the Children’s Hospital in Boston, Massachusetts. Dr Goldstein is a member of the American Academy of Pediatrics, the American Society of Nephrology, the International Pediatric Nephrology Association, the American Society of Pediatric Nephrology, the International Society of Nephrology, and the Society for Pediatric Research. In addition, he is Chairman of the Medical Advisory Committee to the FORUM of ESRD Networks and a member of the Medical Review Board for the ESRD Networks 9 and 10, is the Pediatric Nephrologist Representative for the International Society of Nephrology Commission of Acute Renal Failure, and has been elected to the Council of the American Society of Pediatric Nephrology. Dr Goldstein has developed and validated the pediatric modified RIFLE (pRIFLE) AKI criteria, is Founder and Principal Investigator for the Prospective Pediatric Continuous Renal Replacement Therapy (ppCRRT) Registry Group, and has evaluated novel urinary AKI biomarkers in the pediatric critical care setting. He has written over 110 journal articles and contributed book chapters to numerous texts including, Critical Care Nephrology, Evidence-Based Nephrology, Handbook of Dialysis Therapy, Management of Acute Kidney Problems, Pediatric Critical Care, Pediatric Nephrology, and Pediatric Nephrology in the ICU.

Advisor/Consultant: Baxter; Gambro

Speaker: Gambro

Grant/Research Support: Amgen; Baxter; Gambro

Charles A Herzog, MD, is Director of the Cardiovascular Special Studies Center, United States Renal Data System (USRDS). An investigator at the USRDS since 1999, Dr Herzog has been a cardiologist at Hennepin County Medical Center (HCMC) in Minneapolis and a member of the University of Minnesota faculty for 27 years. He has been a professor of medicine at the University of Minnesota since 2004 and the cardiology consultant to the ESRD program (dialysis and renal transplant) at HCMC since 1985. He founded the program in interventional cardiology and served as the director of the cardiac catheterization laboratory at HCMC from 1985 to 1991. Since 1997, Dr Herzog has been the director of the cardiac ultrasound laboratory at HCMC. He participated in the development of the National Kidney Foundation’s K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients, and co-chaired the 2010 KDIGO Controversies Conference, ‘‘Cardiovascular Disease in CKD: What is it and What Can We Do About It?’’ The author or co-author of more than 100 published papers and reviews, Dr Herzog has served on the Editorial Board for the American Heart Journal since 2005 and as liaison editor (cardiology) for Nephrology Dialysis Transplantation since 2007. His areas of research and special interests include cardiac disease and chronic kidney disease, and echocardiography.

Advisor/Consultant: Abbott; Affymax; Amgen; CorMedix; FibroGen; Fresenius

Board of Trustees: Roche Foundation for Anemia Research Honorarium: UpToDate

Grant/Research Support: Johnson & Johnson; National Institutes of Health

Equity Interest: Boston Scientific; Cambridge Heart; Johnson & Johnson; Merck

Michael Joannidis, MD, is Associate Professor in Medicine and serves as Director of the Medical Intensive Care Unit, Dept. Internal Medicine I at Medical University Innsbruck in Austria. He is a certified specialist in critical-care medicine, nephrology, and cardiology, and his research interests cover several aspects of critical-care medicine with a major focus on AKI, renal tubular epithelial pathophysiology, RRT, and sepsis.

Dr Joannidis currently serves as chair of the section Acute Kidney Injury of the European Society of Intensive Care Medicine (ESICM), President of the Austrian Society of Medical and General Intensive Care Medicine (OEGIAIM) and associate editor of Intensive Care Medicine.

Speaker: Baxter; Fresenius; Gambro

Andreas Kribben, MD, is Professor of Medicine and Head of the Department of Nephrology at the University Hospital Essen at the University of Duisburg-Essen. He received his medical degree at the Johann-Wolfgang Goethe University Frankfurt, Germany in 1983. Dr Kribben was trained in Internal Medicine and Nephrology at the Department of Nephrology of the University Hospital Klinikum Steglitz, Free University of Berlin, Germany and at the University Hospital Essen, University Duisburg-Essen, Germany. From 1990 to 1993, he was a research fellow at the Renal Division of the University of Colorado Health Sciences Centre in Denver, Colorado, USA. His major scientific interests include all aspects of AKI, CRF, as well as transplantation and hypertension.

Dr Kribben is member of numerous professional organizations, including the International Society of Nephrology, the American Society of Nephrology, the European Dialysis and Transplantation Association, and he is a member of the Board of Directors of the German Society of Nephrology. He is an editorial member of Clinical Nephrology and served as subject editor of Nephrology Dialysis Transplantation. Dr Kribben is also a member of the World Health Organization Work Group for the 11th revision of ICD.

Advisor/Consultant: Roche; Shire; Teva

Speaker: Amgen; Apherese ForschungsInstitut; Baxter; Bayer-Schering; Berlin-Chemie; Fresenius; GE Healthcare; Genzyme; Roche; Shire

Grant/Research Support: B. Braun; Biosite; Fresenius; Koehler; Roche; Teva

Andrew S Levey, MD, is Dr Gerald J. and Dorothy R. Friedman Professor of Medicine at Tufts University School of Medicine, Chief of the William B. Schwartz, MD Division of Nephrology at Tufts Medical Center, Senior Scientist at the US Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, and Professor, Clinical Research at the Sackler School of Graduate Biomedical Sciences at Tufts University. His research is mainly in the areas of epidemiology of CKD and cardiovascular disease in CKD, controlled trials to slow the progression of CKD, clinical assessment of kidney function, assessment and improvement of outcomes in dialysis and transplantation, and clinical practice guideline development and implementation. Dr Levey is currently Program Director for an NIDDK-funded clinical research training program, ‘‘Clinical Trials, Epidemiology and Outcomes Research in Nephrology’’. He is also the Director of the Tufts Center for Guideline Development and Implementation and Editor of the American Journal of Kidney Disease. Dr Levey is past Chair of the NKF’s Task Force on Cardiovascular Disease in Chronic Renal Disease, KDOQI Work Group on Chronic Kidney Disease: Evaluation, Classification and Stratification, and KDOQI Work Group on Hypertension and Antihypertensive Agents in Chronic Kidney Disease.

Grant/Research Support: Amgen; National Institutes of Health; National Kidney Foundation

Alison M MacLeod, MBChB, MD, FRCP London and Edinburgh, is Professor in the Department of Medicine and Therapeutics at the University of Aberdeen Medical School, UK. She completed her fellowship at the Royal Colleges of Physicians of London and Edinburgh, and has interests in epidemiology of CKD, AKI, and evidence based medicine in nephrology. Her research group also conducts systematic literature reviews and she is a member of the Editorial Board of the Cochrane Review Group. Dr MacLeod is a current committee member of the European Renal Registry Executive Committee, Anemia Management in Chronic Kidney Disease–National Institute for Health and Clinical Excellence, Scientific Committee, and European Renal Association Congress. In addition, she is Chairman of the Scottish Intercollegiate Guidelines Network, Diagnosis and Management of Chronic Renal Failure and was a member of the Executive Committee of KDIGO.

Dr MacLeod reported no relevant financial relationships.

Ravindra L Mehta, MD, FACP, FASN, FRCP, is Professor of Medicine in the Division of Nephrology and Associate Chair for Clinical Research in the Department of Medicine at the University of California, San Diego (UCSD) where he directs the Acute Dialysis Program and the UCSD CREST and Masters in Clinical Research Program. He received the M.B.B.S. degree (1976) from the Government Medical School in Amritsar, India, and the M.D. (1979) and D.M. (1981) degrees from the Post-Graduate Institute of Medical Education and Research in Chandigarh, India. He subsequently completed a nephrology fellowship at the University of Rochester in Rochester, New York and obtained his boards in internal medicine (1986) and Nephrology (1988). He has been on the faculty at UCSD since 1988.

Dr Mehta is an internationally recognized expert in the field of ARF and has directed several clinical studies in the management of patients with kidney disease including comparing different dialytic modalities in the treatment of AKI, conducting large multicenter observational studies of AKI with the PICARD group, evaluating different predictive models for outcomes in AKI, investigating the role of cytokine removal by dialysis membranes in sepsis and AKI, and evaluating techniques for determining the amount of excess fluid in dialysis patients. In addition to his clinical and research activities, he has worked with the American Society of Nephrology, NKF, Society of Critical Care Medicine, and the International Society of Nephrology in developing courses for fellows and practicing physicians in clinical nephrology and dialysis techniques. Dr Mehta chairs the annual International Conference on CRRT that is now in its 15th year and he is also the Chair of the International Society of Nephrology Committee on AKI, founding member of the ADQI and AKIN. He has authored over 150 scientific articles, papers and book chapters, and has been actively involved in resident and scholar teaching. He won the house staff teaching award on four occasions and was awarded School of Medicine Faculty teaching award in 2003. He has been recognized as one of the Best Doctors in San Diego and the USA. In 2008, he was recognized by the American Nephrologists of Indian Origin for his achievements in nephrology. In March 2009, he was elected as a Fellow of the Royal College of Physicians in the UK. Over the course of his academic career, he has trained over 50 postdoctoral fellows in nephrology, of whom 15 have carried out their research projects with him.

Advisor/Consultant: Astute Medical; Eli Lilly; Takeda

Speaker: Baxter; Gambro

Grant/Research Support: Eli Lilly

Patrick T Murray, MD, FASN, FRCPI, FJFICMI, is a nephrologist and clinical pharmacologist at the Mater Misericordiae University Hospital and University College Dublin, Ireland. Dr Murray received his medical education at University College Dublin, Ireland and following his internship at the Mater Misericordiae University Hospital in Dublin, he completed his residency in internal medicine at Hennepin CountyMedical Center in Minneapolis,Minnesota, USA and fellowship training programs in nephrology, critical care medicine, and clinical pharmacology at the University of Chicago Hospitals in Chicago, Illinois, USA.

Dr Murray is board-certified in internal medicine, nephrology, critical care medicine, and clinical pharmacology and practiced as an intensivist, nephrologist, and clinical pharmacologist at the University of Chicago Hospitals from 1996 to 2008, serving as the fellowship training program director in nephrology and also directing the Acute Dialysis Service. Since 2008, he has been the Professor of Clinical Pharmacology at University College Dublin, and a Consultant in Nephrology & Clinical Pharmacology at the Mater Misericordiae University Hospital. Dr Murray has published extensively with contributions in numerous books including, Critical Care Nephrology, Evidence-Based Nephrology, Evidence-Based Practice of Critical Care, and Intensive Care in Nephrology. He has a long-standing interest in research and education to improve the prevention, diagnosis, and therapy of AKI.

Advisor/Consultant: Abbott; Alere; AM Pharma; Argutus Medical; FAST Diagnostics; Reata; Sanofi-Aventis

Grant/Research Support: Abbott; Alere; Argutus Medical

Saraladevi Naicker, MBChB, MRCP, FRCP, FCP (SA), PhD, is currently Academic Head of the Department of Internal Medicine and Professor of Renal Medicine and head of the Division of Nephrology at the University of the Witwatersrand in Johannesburg. She completed her undergraduate and postgraduate medical training primarily at the University of Natal in Durban, South Africa and spent short periods training in nephrology at the Universities of the Witwatersrand, Johannesburg and Newcastle on Tyne in the UK. She currently chairs the Postgraduate (Higher Degrees) Committee of the Faculty of Health Sciences at the University of the Witwatersrand and is a member of the Council of the College of Physicians of the Colleges of Medicine of South Africa. She is also a Council member of the International Society of Nephrology (ISN) and chairs its Education Committee.

Dr Naicker was the recipient of the Philip Tobias/Convocation Distinguished Teachers Award at the University of the Witwatersrand in 2006, the International Distinguished Medal of NKF of the USA in 2005 and was awarded the prestigious Roscoe Robinson award for nephrology education by the ISN at its World Congress in Milan in May 2009. She has hosted the nephrology training of ISN Fellows from Ethiopia, Nigeria, Botswana, Tanzania, Rwanda, Kenya and Zambia as well as ISPD trainees from Nigeria and Tanzania. During her period as Chair of the Africa Committee of ISN COMGAN from 2000 to 2007, she made site visits and participated in continuing medical education programs in many African countries. Her research interests include areas related to HIV and kidney disease, prevention of CKD, CVD in renal disease, and medical education.

Advisor/Consultant: Amgen; Novartis; Roche

Steven M Opal, MD, is Professor of Medicine at The Warren Alpert Medical School of Brown University and Chief of the Infectious Disease Division, Memorial Hospital of Rhode Island. He received his medical degree from Albany Medical School, Albany, New York and completed his fellowship training in infectious diseases at Walter Reed Army Medical Center in Washington, DC. Dr Opal is a member of numerous national and international committees including, International Steering Committee for Sepsis Clinical Trials; Steering Committee FDA Meta-analysis Committee on Sepsis; International Endotoxin Society; and International Sepsis Forum. He has written extensively with over 300 publications and has given more than 100 invited presentations. Dr Opal currently serves on the editorial boards of Advances in Sepsis, Critical Care Forum, Current Opinion in Critical Care, and Shock. In recognition for his work, he was awarded the Brown Medical School Infectious Disease Fellowship Teacher of the Year Award in 2008 and was acknowledged in Best Doctors in America from 2003 to 2009.

Dr Opal reported no relevant financial relationships.

Franz Schaefer, MD, is Professor of Pediatrics and Chief of the Pediatric Nephrology Division at Heidelberg University Hospital. Dr Schaefer received his M.D. at Wu¨rzburg University Medical School and performed research scholarships at the Institute of Child Health, London, University of Virginia, and Stanford University. His research interests include topics on physiopathology of growth failure, cardiovascular and endocrine disorders in CKD and the role of genetic abnormalities in congenital kidney disorders. In clinical research, he conducted numerous collaborative clinical trials and established several international consortia such as the the European Study Group on Progressive CKD in Children, the International Pediatric Peritoneal Dialysis Network, and the PodoNet Registry for Steroid Resistant Nephrotic Syndrome. Dr Schaefer has published over 280 articles and book chapters, and co-edited the standard textbooks Comprehensive Pediatric Nephrology and Pediatric Dialysis. He received several prestigious awards for innovative research including the Recklinghausen Prize and the IBM Faculty Award. Dr Schaefer is a current council member of the International Pediatric Nephrology Association and the International Society of Peritoneal Dialysis. He is a member of several editorial boards and serves as Section Editor for Nephrology Dialysis Transplantation and Pediatric Nephrology.

Dr Schaefer reported no relevant financial relationships.

Miet Schetz, MD, PhD, graduated from the faculty of Medicine of the Catholic University of Leuven, Belgium, after which she specialized in anesthesiology and later in intensive care medicine. Since 1981 she is staff member of the department of Intensive Care Medicine at the University Hospital Leuven (Chair: Greet Van den Berghe) and has been Associate Professor at the Catholic University Leuven since 2000. Dr Schetz completed her PhD thesis on the subject, ‘‘The Hemostatic System and Continuous Renal Replacement Therapy: Mutual Effects’’. Her main field of interest is AKI and its treatment, on which she published several articles.

Grant/Research Support: Gambro

Shigehiko Uchino, MD, PhD, is Associate Professor and Staff Intensivist in the Department of Anesthesiology at Jikei University School of Medicine in Tokyo, Japan. He received his medical degree from Tokyo Medical and Dental University and his PhD from Jikei University School of Medicine. Dr Uchino is a member of the Japanese Society of Intensive Care Medicine, Japanese Association for Acute Medicine, Society of Critical Care Medicine, and the European Society of Intensive Care Medicine. In addition to serving as a reviewer for numerous journals, he has written book chapters in recent texts such as Critical Care Nephrology, Evidence-Based Practice of Critical Care, and Intensive Care in Nephrology. Dr Uchino is also a coinvestigator in the BEST Kidney study.

Dr Uchino reported no relevant financial relationships.

KDIGO Chairs

Kai-Uwe Eckardt, MD, is Professor of Medicine and Chief of Nephrology and Hypertension at the University of Erlangen—Nuremberg, Germany. He received his MD from the Westfalische Wilhelms-Universitat Munster, Germany. In 1993, following postgraduate training in internal medicine, pathology and physiology, he was appointed Assistant Professor of Physiology at the University of Regensburg, Germany. Subsequently, he continued his training in internal medicine and nephrology at the Charite, Humboldt University in Berlin, where he was appointed Associate Professor of Nephrology in 2000. His major scientific interests are in the molecular mechanisms and physiological/pathophysiological relevance of oxygen sensing and the management of anemia. As such, he has contributed to the development of the European Best Practice Guidelines for Anemia Management and participated in the CREATE and TREAT studies. Professor Eckardt is subject editor of Nephrology Dialysis Transplantation and serves on the editorial board of several other journals. He has also authored book chapters and most recently served as a Co-Editor of the text, Studies on Renal Disorders. Dr Eckardt is a member of the executive committee of KDIGO.

Advisor/Consultant: Affymax; Amgen; Hexal Sandoz; Johnson & Johnson; Roche

Speaker: Amgen; Janssen Cilag; Johnson & Johnson; Roche Grant/Research Support: Roche

Bertram L Kasiske, MD, is Professor of Medicine at the University of Minnesota, USA. He received his medical degree from the University of Iowa and completed his Internal Medicine residency and fellowship training in Nephrology at Hennepin County Medical Center where he is currently Director of Nephrology.

Dr Kasiske is former Deputy Director of the United States Renal Data System and former Editor-in-Chief of The American Journal of Kidney Diseases. He has served as Secretary/Treasurer and on the Board of Directors of the American Society of Transplantation, and on the Organ Procurement and Transplantation Network/United Network of Organ Sharing Board of Directors, and the Scientific Advisory Board of the National Kidney Foundation. He is currently serving on the Board of Councilors of the International Society of Nephrology. He is the Principal Investigator for a National Institutes of Health-sponsored, multi-center study of long term outcomes after kidney donation. He is the Director of the Scientific Registry of Transplant Recipients. He has over 160 scientific publications in major peer reviewed journals, and 230 review articles, editorials and textbook chapters. Dr Kasiske is also a recipient of the NKF’s Garabed Eknoyan Award in 2003.

Advisor/Consultant: Litholink

Grant/Research Support: Bristol-Myers Squibb; Merck-Schering Plough

Evidence Review Team

Katrin Uhlig, MD, MS, is the Director, Guideline Development at the Tufts Center for Kidney Disease Guideline Development and Implementation, Boston, MA, Associate Professor of Medicine at Tufts University School of Medicine, and a staff nephrologist at Tufts Medical Center. Dr Uhlig completed her training in internal medicine, nephrology, and rheumatology in Germany (Aachen University Hospital and Munich University Hospital) and the USA (Georgetown University Medical Center and Tufts Medical Center). Since 2001, she has been participating in or directing the evidence review for KDOQI and KDIGO guidelines. In 2005, she co-chaired the KDIGO Evidence Rating Group to develop a consensus on grading of KDIGO guidelines. From 2006 to 2007, she served as Co-Editor of the American Journal of Kidney Diseases. Her focus in teaching and research is in evidence-based medicine, systematic review, clinical practice guideline development, and critical literature appraisal.

Dr Uhlig reported no relevant financial relationships.

Jose Calvo-Broce, MD, MS, served as a research fellow at the Tufts Center for Kidney Disease Guideline Development and Implementation in Boston, MA and participated in the conduct of systematic reviews and critical literature appraisals for this guideline. Dr Calvo-Broce was recently awarded a Master of Science in Clinical Research for his thesis on ‘‘Hospital-Acquired AKI: An Analysis of Nadir-to-Peak Serum Creatinine Increments Stratified by Baseline Estimated GFR’’.

Dr Calvo-Broce reported no relevant financial relationships.

Aneet Deo, MD, MS, served as a research fellow at the Tufts Center for Kidney Disease Guideline Development and Implementation in Boston, MA. She participated in the conduct of systematic reviews and critical literature appraisals for this guideline. Dr Deo was awarded a Master of Science in Clinical Research for her thesis on ‘‘Loss to Analysis in Randomized Controlled Trials of Chronic Kidney Disease’’.

Dr Deo reported no relevant financial relationships.

Amy Earley, BS, is a project coordinator at the Tufts Center for Kidney Disease Guideline Development and Implementation in Boston, MA. She assists in the development of clinical practice guidelines and conducts systematic reviews and critical literature appraisals.

Ms Earley reported no relevant financial relationships.

By using this site you acknowledge that you have read, understand, and agree to be bound by our terms of use and privacy policy. All content and tools are for educational use only, are not meant to be a substitute for professional advice and should not be used for medical diagnosis and/or medical treatment.
Advertisement

Contact us

Do you have an enquiry or suggestion? Get in touch with us through Twitter @QxMD, Facebook QxMD, or email contact@qxmd.com

Transfer results and close
Cancel
Linked calculator